Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March
Montreal, Quebec--(Newsfile Corp. - March 2, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum® platform, today outlined its participation in a series of major international industry events taking place in March 2026. These high-profile meetings will provide Defence with multiple opportunities to advance strategic p
Biotechnology, Pharmaceuticals, Health
2026-03-02 3:15 AM EST | Defence Therapeutics Inc.
Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million
Montreal, Quebec--(Newsfile Corp. - February 27, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the launch of a private placement (the "Private Placement") of up to 20,000,000 units (the "Units") at a price of $0.55 per Unit, for aggregate gross proceeds to Defence of up to $11,000,000. Each Unit will be compris
Biotechnology, Pharmaceuticals, Health
2026-02-27 5:00 PM EST | Defence Therapeutics Inc.
TempraMed Reports over 275 Clinicians Recommending VIVI Cap to Patients on Leading FrontrowMD Platform Across the United States
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that more than 275 physicians across the United States have recommended and included VIVI Cap in the offers available to their patients across FrontrowMD, a leading physician engagement and education platform.
Technology, Biotechnology, Pharmaceuticals, Health
2026-02-26 7:00 AM EST | TempraMed Technologies Ltd.
Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today reported that patients diagnosed with treatment-resistant depression (TRD) have now been treated in Australia using the Company's naturally derived 5 mg psilocybin capsules under the Authorised Prescriber Scheme. The clinical a
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-26 7:00 AM EST | Optimi Health Corp.
Optimi Health berichtet über den frühen klinischen Einsatz natürlicher Psilocybin-Kapseln zur Behandlung therapieresistenter Depressionen in Australien
Vancouver, British Columbia--(Newsfile Corp. - Donnerstag, 26. Februar 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" oder das "Unternehmen"), ein von Health Canada lizenzierter Hersteller pharmazeutischer Psychedelika-Produkte in pharmazeutischer Qualität, gab heute bekannt, dass in Australien nun Patienten mit therapieresistenter Depression (TRD) unter dem Authorised Prescriber Scheme mit den natürlich gewonnenen 5-mg-Psilocybin-Kapseln d
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-26 7:00 AM EST | Optimi Health Corp.
PreveCeutical Announces Canadian Patent Office Allowance of Innovative Pain Therapy Technology
Vancouver, British Columbia--(Newsfile Corp. - February 25, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Canadian Patent Office has allowed Canadian Patent Application No. 3127020, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This allowance represents a significant milestone in the protection of PreveCeutical's proprietary technologies aime
Biotechnology, Pharmaceuticals, Health
2026-02-25 3:00 AM EST | PreveCeutical Medical Inc.
Telescope Innovations Installs Second Self-Driving Lab at Pfizer
Vancouver, British Columbia--(Newsfile Corp. - February 23, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a developer of enabling technologies and services for the global pharmaceutical and chemical industries, is pleased to announce the installation of its second Self-Driving Laboratory ("SDL") at Pfizer, as part of the multi-year agreement between the companies. The installation was completed in January 202
Technology, Chemical, Pharmaceuticals
2026-02-23 8:00 AM EST | Telescope Innovations Corp.
Jones Healthcare Group Wins Best of Show and Best in Class Honours at PAC Global Awards for Qube(TM) Eco
London, Ontario--(Newsfile Corp. - February 20, 2026) - As healthcare systems face increasing pressure to reduce waste and carbon impact, packaging innovation must deliver measurable results without compromising patient safety or pharmacy workflow. At the same time, environmental claims across industries are under greater scrutiny, with regulators, retailers and consumers demanding proof over promise. At the 2026 PAC Global Awards ceremony, held February 18-19 in Toronto, Jones Healthca
Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-20 12:36 PM EST | Jones Healthcare Group
Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Toronto, Ontario--(Newsfile Corp. - February 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of canc
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-02-20 7:00 AM EST | Theralase Technologies Inc.
Nextleaf Solutions Scales up CPG Brand Growth with an Enhanced National Commercial Platform
Vancouver, British Columbia--(Newsfile Corp. - February 19, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a multi-patented life science company and Canadian cannabis processor announced strategic enhancements to its commercial infrastructure, including appointment of Kindred Canada as its national sales agency partner, and the addition of enhanced distribution partners serving Manitoba and Saskatchewan. These initiatives
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-02-19 9:00 AM EST | Nextleaf Solutions Ltd.
Neural Therapeutics Announces CSE Application to Acquire Full Ownership of Hanf.com, Shareholder Meeting, SIO Agreement Amendment and Concurrent Financing
Toronto, Ontario--(Newsfile Corp. - February 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce that it has formally applied to the Canadian Securities Exchange (the "CSE") for approval to acquire the remaining 69.25% interest in CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers. Ronnie Jaegermann, Chief Executive Officer of CWE, stated: "Hanf.com h
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-19 8:53 AM EST | Neural Therapeutics Inc.
Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference
Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 3:20 p.m. ET. A live webcast will be available on Kiora's investor relations website, ir.kiorapharma.com, on the
Biotechnology, Pharmaceuticals
2026-02-19 8:30 AM EST | Kiora Pharmaceuticals, Inc.
Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894
King of Prussia, Pennsylvania--(Newsfile Corp. - February 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-19 7:00 AM EST | Phio Pharmaceuticals Corp.
Optimi Health schließt Psilocybin-Export nach Australien zur Behandlung therapieresistenter Depression ab
Vancouver, British Columbia--(Newsfile Corp. - Donnerstag, 19. Februar 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" oder das "Unternehmen"), ein von Health Canada lizenzierter Hersteller von psychedelischen Arzneimitteln in pharmazeutischer Qualität, gab heute den Export seiner nach GMP-Standards hergestellten natürlichen 5-mg-Psilocybin-Kapseln nach Australien bekannt. Diese werden zur Behandlung von Patientinnen und Patiente
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-19 2:00 AM EST | Optimi Health Corp.
Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression
Vancouver, British Columbia--(Newsfile Corp. - February 19, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today announced the export of its GMP-manufactured natural 5 mg psilocybin capsules to Australia for the treatment of patients diagnosed with treatment-resistant depression (TRD) under Australia's Authorised Prescriber Scheme.
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-19 2:00 AM EST | Optimi Health Corp.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - February 17, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the third quarter of fiscal year 2026, the three months ended December 31, 2025 ("Third Quarter"). Consolidated revenues for the three-month period ending December 31, 2025, were $31.6 million, an increase of $17.2 million or approximately 120% as compared
Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-17 4:19 PM EST | Elite Pharmaceuticals, Inc.
Optimi Health Reports First MDMA-Assisted Treatments of 2026 are Underway Across an Expanded Network of Australian Clinics
Vancouver, British Columbia--(Newsfile Corp. - February 17, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that the first patients of 2026 have been treated using the Company's MDMA capsules at authorised clinics across Australia, operating under the Authorised Prescriber Scheme. The Company continues to supply its finished MDMA drug product d
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-17 7:00 AM EST | Optimi Health Corp.
Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that its interim clinical data has been selected for presentation at the 2026 European Association of Urology Cong
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-02-17 7:00 AM EST | Theralase Technologies Inc.
Optimi Health meldet Beginn der ersten MDMA-gestützten Behandlungen im Jahr 2026 in einem erweiterten Netzwerk australischer Kliniken
Vancouver, British Columbia--(Newsfile Corp. - Montag, 16. Februar 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" oder das "Unternehmen"), ein von Health Canada lizenzierter Hersteller pharmazeutischer psychedelischer Arzneimittelprodukte, gab heute bekannt, dass die ersten Patientinnen und Patienten des Jahres 2026 in autorisierten Kliniken in ganz Australien mit den MDMA-Kapseln des Unternehmens behandelt wurden. Die Behandlungen erfolgen im Rahmen des Authorise
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-16 1:00 AM EST | Optimi Health Corp.
Nextleaf Solutions Completes Initial Softgel Shipment to Australia and Announces Global Expansion of Commercial Partners Program(TM)
Vancouver, British Columbia--(Newsfile Corp. - February 13, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a multi-patented life science company and Canadian cannabis processor, is pleased to announce expansion of its Commercial Partners ProgramTM to support global market growth, through completion of an initial softgel shipment to Australia. Nextleaf Announces Initial Softgel Shipment to Australia
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-02-13 9:00 AM EST | Nextleaf Solutions Ltd.